Slide 1: Corporate Presentation June 2026
Corporate Presentation J U N E 2026 N A S D A Q : N X T C
Slide 2: Forward-Looking Statements
Forward-Looking Statements 2 To the extent that statements contained in this presentation are not descriptions of historical facts, they may be deemed to be forward-looking statements under the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations, fore
Slide 3: In the Fight Against Cancer: Harnessing the Power of Targeted Therapy
3 In the Fight Against Cancer Harnessing the Power of Targeted Therapy 3
Slide 4: ADC Pipeline Progress
ADC Pipeline Progress 4 PROGRAMS TARGET PAYLOAD PRECLINICAL PHASE 1 PHASE 2 NEXT MILESTONE SIM0505 CDH6 TOPO 1Q 2027 Dose Optimization Update 4Q 2026 Initiate Dose Optimization LNCB74 B7-H4 MMAE 2H 2026 Trial Progress Co-development with Breast, Ovarian, Endometrial , ACC-1 Ovarian Cancer Uterine Se
Slide 5: Accelerating Toward Pivotal Study
5 Accelerating Toward Pivotal Study ✓ Global exclusive license (ex China) from Simcere Zaiming ✓ Combine US and China data for fast & definitive POC ✓ US, China, Canada and Europe site expansion ✓ CDMO tech transfer initiated PRODUCT DEVELOPMENT SIM0505 ✓ 55% ORR in gynecologic cancers ✓ Completed d
Slide 6: SIM0505 is a Differentiated CDH6 TOPOi ADC
SIM0505 is a Differentiated CDH6 TOPOi ADC 6 Payload CPT116 (TOPO) GGFG Linker CDH6 mAb DAR 8.0 Cysteine conjugation Gly-Gly-Phe-Gly Provides Tumor-Specific Cleavage Unique Binding Epitope with Increased Affinity High Systemic Clearance for Reduced Toxicity Linker Potent Cytotoxicity with Anticipate
Slide 7: SIM0505 Structural and Functional Differentiation by Design
SIM0505 Structural and Functional Differentiation by Design • Unique distal EC1 epitope on CDH6 • Ovarian, uterine, RCC, NSCLC • High affinity & internalization • PK proportionality 7 Membrane EC1 EC2 EC3 EC4 EC5 SIM0505 •Designed for better tolerability & safety •Hydrophilic & high systemic clearan
Slide 8: SIM0505 Development Plan
•ORR (RECIST 1.1) •PFS SIM0505 Development Plan 8 9.6 mg/kg (n = 4) COMPLETED DOSE ESCALATION 2Q 2026 INITIATED DOSE OPTIMIZATION 2Q 2026 PLANNING PIVOTAL TRIAL •Generating recommended pivotal trial dose *TPC: treatment of physician’s choice PROC & USC PROC Q3W 8.0 mg/kg (n = 10) 6.4 mg/kg (n = 13)
Slide 9: SIM0505 Patient Demographics
SIM0505 Patient Demographics Baseline Characteristic US Patients (n = 25) China Patients (n = 34) All Patients (n = 59) Age, years Median (range) 63 (49-78) 56 (42-72) 58 (42-78) Sex, n (%) Male 0 (0.0) 2 (5.9) 2 (3.4) Female 25 (100) 32 (94.1) 57 (96.6) Tumor Type, n (%) Ovarian 19 (76.0) 27 (79.4)
Slide 10: SIM0505 Has Shown a Well Manageable Safety Profile
10 SIM0505 Has Shown a Well Manageable Safety Profile Overview of Adverse Events 1.6 – 9.6 mg/kg (n = 59) n (%) Treatment-emergent adverse events (TEAEs) (%) 59 (100) Grade ≥3 32 (54.2) Grade 5 a 2 (3.4) TEAEs related to study drug (TRAEs) (%) 57 (96.6) Grade ≥3 28 (47.5) Grade 5 0 Any Serious adver
Slide 11: Most Common TEAEs
0 10 20 30 40 50 60 70 Alopecia Asthenia Dyspnoea Hypomagnesaemia Blood bilirubin increased Lymphocyte count decreased Abdominal distension Amylase increased Gamma-glutamyltransferase increased Proteinuria Pyrexia Dizziness Hypertriglyceridaemia Weight decreased Hypoalbuminaemia Alanine aminotransfe
Slide 12: Patient Response Duration Chart
0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 5101016 - HGSOC - 7R 5103005 - HGSOC - 6R 5105006 - HGSOC - 5R 5102008 - RCC - 5R 5104004 - HGSOC - 4R 5208001 - HGSOC - 1R 5105004 - HGSOC - 3R 5203004 - HGSOC - 3R 5206001 - HGSOC - 5R 5103004 - HGSOC - 4R 5201002 - HGEOC - 3R 5203001 - USC - 4R 51030
Slide 13: ORR at 4.8 – 8.0 mg/kg
ORR at 4.8 – 8.0 mg/kg: ≥12 Weeks and Best Response 13 Tumor type Evaluable (n) PRs (n) ORR Gynecologic Cancers (OC + USC) 20 11 55.0% (11/20) Ovarian Cancer (OC) 17 9 52.9% (9/17) Uterine Serous Carcinoma (USC) 3 2 66.7% (2/3)
Slide 14: Gynecologic Cancers Patient Response
0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 5104004 - HGSOC - 4R 5208001 - HGSOC - 1R 5105004 - HGSOC - 3R 5203004 - HGSOC - 3R 5206001 - HGSOC - 5R 5103004 - HGSOC - 4R 5201002 - HGEOC - 3R 5203001 - USC - 4R 5103003 - HGSOC - 3R 5105003 - HGSOC - 2R 5205007 - HGSOC - 2R 5103006 - HGSOC - 4R 520
Slide 15: Ovarian Cancer at Therapeutic Doses (4.8 – 8.0 mg/kg)
• n = 37 ovarian cancer patients • Patients with at least ≥12 weeks follow-up • Other: 1 PR 9.6 mg/kg Ovarian Cancer at Therapeutics Doses (4.8 – 8.0 mg/kg) 15 Weeks on Treatment HGSOC: high-grade serous ovarian cancer; HGEOC: high-grade endometroid cancer; LGSOC: low-grade serous ovarian cancer On
Slide 16: Ovarian Cancer (4.8 – 8.0 mg/kg) Tumor Change
17.4 2.6 0.0 -9.1 -14.0 -14.9 -15.0 -27.2 -34.0 -41.6 -47.1 -50.2 -52.2 -53.7 -62.0 -68.4 -70.0 -75 -60 -45 -30 -15 0 15 30 5103004 / HGSOC / 5R 5204001 / HGSOC-FT / 3R 5201002 / HGEOC / 4R 5203004 / HGSOC / 4R 5104007 / HGSOC / 4R 5102009 / HGSOC / 5R 5101009 / LGSOC / 3R 5104006 / HGSOC / 10R 5103
Slide 17: Ovarian Cancer (4.8 – 8.0 mg/kg) Tumor Shrinkage Over Time
0 6 12 18 24 30 36 -75 -60 -45 -30 -15 0 15 30 45 Weeks on Treatment Ovarian Cancer (4.8 – 8.0 mg/kg) 17 • Most patients (15/17) had tumor shrinkage • Increasing tumor shrinkage with continued treatment • The greatest tumor shrinkage and durability occurred at 6.4mg/kg Tumor Percent Change from Base
Slide 18: Uterine Serous Carcinoma (4.8 – 8.0 mg/kg)
• n = 6 USC patients enrolled • Patients with at least ≥12 weeks follow-up • Other: ̶1 PR 1.6 mg/kg ̶1 PR 7.2 mg/kg (has not reached 12 weeks) 18 Uterine Serous Carcinoma (4.8 – 8.0 mg/kg) On treatment Evaluable PR ORR n = 3 2 66.7% 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 5203001 - USC - 4R 5
Slide 19: SIM0505 Development Plan: Dose Optimization
•ORR (RECIST 1.1) •PFS SIM0505 Development Plan: Dose Optimization 19 9.6 mg/kg (n = 4) COMPLETED DOSE ESCALATION INITIATED DOSE OPTIMIZATION PLANNING PIVOTAL TRIAL •Generating recommended pivotal trial dose *TPC: treatment of physician’s choice PROC & USC PROC Q3W 8.0 mg/kg (n = 10) 6.4 mg/kg (n =
Slide 20: SIM0505 Roadmap to Potential Best-in-Class CDH6 ADC
20 SIM0505 Roadmap to Potential Best-in-Class CDH6 ADC ✓ Initiated dose optimization (5.6, 6.4 & 7.2 mg/kg) ✓ Additional sites in US, China, Canada & 4 European countries ✓ Securing supply chain & preparing for pivotal study ✓ RCC and NSCLC potential near-term development expansions PRODUCT DEVELOPM
Slide 21: Opportunity to Develop Differentiated CDH6 ADC Therapeutic
POTENTIAL FOR IMPROVED SAFETY & EFFICACY Opportunity to Develop Differentiated CDH6 ADC Therapeutic 21 CDH6 ADC ONGOING DOSE OPTIMIZATION TRIAL IN US & CHINA UPDATE DOSE OPTIMIZATION 1Q 2027 SIM0505
Slide 22: LNCB74 – B7-H4 ADC for Ovarian Cancer
22 LNCB74 – B7-H4 ADC for Ovarian Cancer ONGOING DOSE ESCALATION • Differentiated ADC with unique linker • Trial ongoing in US • CLIA validated IHC assay for patient selection PLANNING DOSE OPTIMIZATION • 2 doses • 80 patients • Defining recommended Ph2 dose
Slide 23: LNCB74 is a Differentiated Anti-B7-H4 MMAE ADC
LNCB74 is a Differentiated Anti-B7-H4 MMAE ADC Fc Modification Protects immune cells Tumor Selectivity Glucuronidase cleavable linker provides improved safety & increased efficacy 23 MMAE DAR 4 Improves targeted release and safety Antibody Linker Payload STRUCTURAL DIFFERENTIATION
Slide 24: LNCB74 Uses Differentiating Glucuronidase Linker
LNCB74 Uses Differentiating Glucuronidase Linker Designed for Improved Safety & Increased Efficacy 24 Bloodstream Tissues Cancer Cell Bystander Effect Linker Glucuronidase cleavable Payload Tubulin inhibitor Conjugation Site Specific DAR 4 •Efficient release of toxin •Higher concentration Stable Pot
Slide 25: LNCB74 Showed Potent Anti-Tumor Activity in CDX and PDX Models
25 LNCB74 Showed Potent Anti-Tumor Activity in CDX and PDX Models OVARIAN (OVCAR-3-B7-H4-OE) Days from Treatment Initiation Mean Volume (mm3) +/- SEM TNBC (CTG-0012) Mean Volume (mm3) +/- SEM Days from Treatment Initiation BREAST (ZR-75-1) Days from Treatment Initiation Mean Tumor Volume (mm3) +/- S
Slide 26: LNCB74 Development Plan
LNCB74 Development Plan 26 Cohort 6 ONGOING DOSE ESCALATION PLANNING DOSE OPTIMIZATION • Recommended pivotal trial dose Q3W Breast, Ovarian, Endometrial, ACC-1 Cohort 5 Cohort 4 Cohort 3 Cohort 2 Cohort 1 TOTAL n = 54 TOTAL n = 80 Dose Level X Dose Level Y 2 Tumor Types ACC-1: Adenoid Cystic Carcino
Slide 27: Advancing LNCB74 Development
Advancing LNCB74 Development Cohort 1 Cohort 2 Cohort 3 Cohort 4 Backfill Cohorts 27 Dose Expansion • 6 dose cohorts • Regimen Q3W • n = 54 subjects • 2 dose cohorts • 2 tumor types • n = 80 subjects • Pre & on treatment biopsies Patient selection strategy Patient selection strategy Dose Escalation
Slide 28: Product Life Cycle Management: Options to Address Resistance
28 Product Life Cycle Management: Options to Address Resistance LNCB74 B7-H4 Tubulin inhibitor SIM0505 CDH6 Topoisomerase 1 inhibitor CONCURRENT ADMINISTRATION COMBO SEQUENCED ADMINISTRATION OR LNCB74 SIM0505 LNCB74 SIM0505 SIM0505 LNCB74 OR
Slide 29: Opportunity to Develop Differentiated B7-H4 ADC Therapeutic
DESIGNED TO IMPROVE SAFETY & INCREASE EFFICACY Opportunity to Develop Differentiated B7-H4 ADC Therapeutic 29 B7-H4 ADC UNMET NEED IN BREAST & GYNECOLOGICAL CANCERS PATIENT SELECTION STRATEGY
Slide 30: Programs Available for Partnering
Programs Available for Partnering 30 PROGRAMS TARGET CELLS DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 NC410 Combo LAIR-2 Extracellular Matrix NC525 LAIR-1 Leukemia NC605 S15 Osteoclasts NC181 APOE4 Microglia & Neurons Alzheimer’s Disease Osteogenesis Imperfecta Acute Myeloid Leukemia Colorectal (
Slide 31: Expected Milestones & Deliverables
31 Expected Milestones & Deliverables • SIM0505 (CDH6) update dose optimization in PROC 1Q 2027 and initiate dose optimization in USC 4Q 2026 • LNCB74 (B7-H4) trial progress update in 2H 2026 (Breast, Ovarian, Endometrial and ACC-1) 2026 UPDATES PHASE 1 CLINICAL ASSETS • SIM0505 and B7-H4 ADCs • Dif